MAMatheus Aranguren

Matheus Aranguren

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Matheus Aranguren has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Aeshah Alluli

    Early Drug Discovery Unit, Montreal Neurological Institute-Hospital, McGill University, Montreal, QC, Canada

    1 shared publication
  • Alexandre Villard

    Center for Immunity, Inflammation and Infectious Diseases, Montreal Clinical Research Institute / Institut de Recherches Cliniques de Montréal (IRCM); Montreal, QC, Canada

    1 shared publication
  • Aléhandra Desjardins

    Center for Immunity, Inflammation and Infectious Diseases, Montreal Clinical Research Institute / Institut de Recherches Cliniques de Montréal (IRCM); Montreal, QC, Canada

    1 shared publication
  • Chantal Massé

    Center for Immunity, Inflammation and Infectious Diseases, Montreal Clinical Research Institute / Institut de Recherches Cliniques de Montréal (IRCM); Montreal, QC, Canada

    1 shared publication
  • Charlotte DuSablon

    Center for Immunity, Inflammation and Infectious Diseases, Montreal Clinical Research Institute / Institut de Recherches Cliniques de Montréal (IRCM); Montreal, QC, Canada

    1 shared publication
  • Diana Cabrera Munoz

    Center for Immunity, Inflammation and Infectious Diseases, Montreal Clinical Research Institute / Institut de Recherches Cliniques de Montréal (IRCM); Montreal, QC, Canada

    1 shared publication

Latest Publications

  • Open Access

    Microbiota-derived extracellular vesicles link intestinal dysbiosis to neuroimmune activation in long COVID

    by Matheus Aranguren, Kim Doyon-Laliberté, Idia Boncheva, Alexandre Villard, Aléhandra Desjardins, Emma Darbinian, Suhani Patel, Charlotte DuSablon, Estefania Rivera Conde, Diana Cabrera Munoz, et al.

    Summary: Post COVID-19 condition (Long COVID, LC) is frequently accompanied by persistent neurological symptoms, but the mechanisms linking intestinal dysbiosis to neuroinflammation remain unclear. Here we identify gut microbiota-derived extracellular vesicles (GMEVs) as functional mediators linking LC-associated dysbiosis to systemic and neuroimmune inflammation. In a longitudinally characterized cohort, individuals with LC and neurological symptoms exhibit a persistent intestinal microbiome signature. Transplantation of LC-associated microbiota into germ-free mice induces intestinal barrier disruption and neuroinflammatory phenotypes. GMEVs from individuals with LC activate inflammasome-associated programs and impair epithelial barrier function, promote inflammatory responses in macrophages, and induce coordinated pro-inflammatory transcriptional programs in human induced pluripotent stem cell (iPSC)-derived microglia. Chronic oral administration of LC-derived GMEVs remodels the microbiota and induces intestinal and systemic inflammation with glial activation in vivo . Together, these findings support a vesicle-centered framework in which microbiota-derived extracellular vesicles translate dysbiosis into sustained immune and neuroimmune activation in a post-viral inflammatory state.